NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enveda Biosciences

Enveda Biosciences

Private
Boulder, ColoradoHealthcare & Life Scienceshttps://enveda.com/

Last Round

Series D

Sep 4, 2025

Est. Valuation

$1B

Total Funding Raised

$600.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Enveda Biosciences is a biotechnology company that utilizes an AI-powered drug discovery platform to analyze natural samples for chemical structure and biological activity to develop novel small-molecule medicines.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Foundation

Keywords

AI drug discoverynatural product discoveryAI biotechdrug discovery platformbioactive molecule discoverymetabolomicsdrug pipelinemass spectrometry AIfoundation modelgenerative biologymedicinal plant chemistrypharmaceutical partnershipsNagoya Protocol

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enveda Biosciences Comparables

Compare Enveda Biosciences with similar companies based on industry and business-model similarity.

Enveda Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Insitro
81%
LifeMine Therapeutics
79%
Insilico
79%

Enveda Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 4, 2025
Series C ExtensionFeb 26, 2025
Series CNov 21, 2024
Series B ExtensionJun 14, 2024
Series B ExtensionApr 20, 2023
Series B
Dec 21, 2022

Key People

Founding team and executive leadership

August Allen

Chief Technology Officer

Executive Team

Hannah Gordon

Chief Product Officer, Vice President Of Product

Executive Team

Enveda Biosciences Investors

Notable investors and investment history

Enveda Biosciences investors
InvestorRounds
S32Series B Extension
LingottoSeries B Extension, Series D, Series C
Global VillageSeed, Series A
Wireframe VenturesSeries B, Series A, Seed, Series B Extension
Lingotto InnovationSeries C Extension, Series C
DimensionSeries D
JAZZ Venture PartnersSeries B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 8, 2026

    ENV-294 is one of the lead assets in clinical trials.

  • Jan 1, 2026

    Named one of Fast Company's Most Innovative Companies in 2026.

Enveda Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enveda Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enveda Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoulder, Colorado
Employee Range389
Year Founded2019
Last FundingSep 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.